|
1
|
Yue QX, Liu X and Guo DA:
Microtubule-binding natural products for cancer therapy. Planta
Med. 76:1037–1043. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bitis L, Kultur S, Melikoglu G, Ozsoy N
and Can A: Flavonoids and antioxidant activity of Rosa agrestis
leaves. Nat Prod Res. 24:580–589. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Androutsopoulos VP and Spandidos DA: The
flavonoids diosmetin and luteolin exert synergistic cytostatic
effects in human hepatoma HepG2 cells via CYP1A-catalyzed
metabolism, activation of JNK and ERK and P53/P21 up-regulation. J
Nutr Biochem. 24:496–504. 2013. View Article : Google Scholar
|
|
4
|
Rice-Evans CA, Miller NJ and Paganga G:
Structure-antioxidant activity relationships of flavonoids and
phenolic acids. Free Radic Biol Med. 20:933–956. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Quintieri L, Bortolozzo S, Stragliotto S,
Moro S, Pavanetto M, Nassi A, Palatini P and Floreani M: Flavonoids
diosmetin and hesperetin are potent inhibitors of cytochrome P450
2C9-mediated drug metabolism in vitro. Drug Metab Pharmacokinet.
25:466–476. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Obmann A, Werner I, Presser A, Zehl M,
Swoboda Z, Purevsuren S, Narantuya S, Kletter C and Glasl S:
Flavonoid C-and O-glycosides from the Mongolian medicinal plant
Dianthus versicolor Fisch. Carbohydr Res. 346:1868–1875. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang JD and Roberts LR: Hepatocellular
carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448–458.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Poon RT and Borys N: Lyso-thermosensitive
liposomal doxorubicin: An adjuvant to increase the cure rate of
radiofrequency ablation in liver cancer. Future Oncol. 7:937–945.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Androutsopoulos VP, Mahale S, Arroo RR and
Potter G: Anticancer effects of the flavonoid diosmetin on cell
cycle progression and proliferation of MDA-MB 468 breast cancer
cells due to CYP1 activation. Oncol Rep. 21:1525–1528.
2009.PubMed/NCBI
|
|
10
|
Androutsopoulos V, Wilsher N, Arroo RR and
Potter GA: Bioactivation of the phytoestrogen diosmetin by CYP1
cytochromes P450. Cancer Lett. 274:54–60. 2009. View Article : Google Scholar
|
|
11
|
Androutsopoulos VP, Ruparelia K, Arroo RR,
Tsatsakis AM and Spandidos DA: CYP1-mediated antiproliferative
activity of dietary flavonoids in MDA-MB-468 breast cancer cells.
Toxicology. 264:162–170. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Drabsch Y and ten Dijke P: TGF-β signaling
in breast cancer cell invasion and bone metastasis. J Mammary Gland
Biol Neoplasia. 16:97–108. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Busse A and Keilholz U: Role of TGF-β in
melanoma. Curr Pharm Biotechnol. 12:2165–2175. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Heldin CH, Landström M and Moustakas A:
Mechanism of TGF-beta signaling to growth arrest, apoptosis, and
epithelial-mesenchymal transition. Curr Opin Cell Biol. 21:166–176.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Meulmeester E and ten Dijke P: The dynamic
roles of TGF-β in cancer. J Pathol. 223:205–218. 2011. View Article : Google Scholar
|
|
16
|
Zhang Q, Liu J, Liu B, Xia J, Chen N, Chen
X, Cao Y, Zhang C, Lu C, Li M and Zhu R: Dihydromyricetin promotes
hepato-cellular carcinoma regression via a p53 activation-dependent
mechanism. Sci Rep. 4:46282014.
|
|
17
|
Wu S, Liu B, Zhang Q, Liu J, Zhou W, Wang
C, Li M, Bao S and Zhu R: Dihydromyricetin reduced Bcl-2 expression
via p53 in human hepatoma HepG2 cells. PloS One. 8:e768862013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar
|
|
19
|
Brady CA, Jiang D, Mello SS, Johnson TM,
Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ,
McLaughlin ME, et al: Distinct p53 transcriptional programs dictate
acute DNA-damage responses and tumor suppression. Cell.
145:571–583. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Harvey AL: Natural products in drug
discovery. Drug Discov Today. 13:894–901. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ciolino HP, Wang TT and Yeh GC: Diosmin
and diosmetin are agonists of the aryl hydrocarbon receptor that
differentially affect cytochrome P450 1A1 activity. Cancer Res.
58:2754–2760. 1998.PubMed/NCBI
|
|
22
|
Takeuchi H, Yokota A, Ohoka Y and Iwata M:
Cyp26b1 regulates retinoic acid-dependent signals in T cells and
its expression is inhibited by transforming growth factor-β. PloS
One. 6:e160892011. View Article : Google Scholar
|
|
23
|
Nagaraj NS and Datta PK: Targeting the
transforming growth factor-beta signaling pathway in human cancer.
Expert Opin Investig Drugs. 19:77–91. 2010. View Article : Google Scholar
|
|
24
|
Perrot CY, Javelaud D and Mauviel A:
Insights into the transforming growth factor-β signaling pathway in
cutaneous melanoma. Ann Dermatol. 25:135–144. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Speidel D: Transcription-independent p53
apoptosis: An alternative route to death. Trends Cell Biol.
20:14–24. 2010. View Article : Google Scholar
|
|
26
|
Javelaud D, Alexaki VI, Dennler S,
Mohammad KS, Guise TA and Mauviel A: TGF-β/SMAD/GLI2 signaling axis
in cancer progression and metastasis. Cancer Res. 71:5606–5610.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee JH, Gaddameedhi S, Ozturk N, Ye R and
Sancar A: DNA damage-specific control of cell death by cryptochrome
in p53-mutant ras-transformed cells. Cancer Res. 73:785–791. 2013.
View Article : Google Scholar
|
|
28
|
Burmakin M, Shi Y, Hedström E, Kogner P
and Selivanova G: Dual targeting of wild-type and mutant p53 by
small molecule RITA results in the inhibition of N-Myc and key
survival oncogenes and kills neuroblastoma cells in vivo and in
vitro. Clin Cancer Res. 19:5092–5103. 2013. View Article : Google Scholar : PubMed/NCBI
|
